AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39323439 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported non-smoking status with eCO concentration <6 ppm
Number of subjects: 1291
Study 39323439 — intervention group
Group type: COMPARATOR
Intervention: Self-reported smoking status with eCO concentration <6 ppm
Number of subjects: 1291
Study 39323439 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated eCO concentration (≥6 ppm)
Number of subjects: 1291
Study 39323753 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVSs)
Number of subjects: 240
Study 39323753 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (DES)
Number of subjects: 240
Study 39323753 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents (BESs)
Number of subjects: 240
Study 39323780 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokeratology (OK) lenses
Number of subjects: 300
Study 39323780 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 300
Study 39324115 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Takotsubo syndrome (TTS) event
Number of subjects: 88
Study 39324520 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported hearing loss in CN participants
Number of subjects: 1636
Study 39324520 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported hearing loss in CN and MCI participants
Number of subjects: 1636
Study 39324668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-target HCC blood test (DT-HBT)
Number of subjects: 1030
Study 39324693 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cotrimoxazole prophylaxis plus mefloquine
Number of subjects: 4976
Study 39324693 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cotrimoxazole prophylaxis plus dihydroartemisinin/piperaquine
Number of subjects: 4976
Study 39324726 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Number of subjects: 0
Study 39324726 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 0
Study 39324933 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) treatment
Number of subjects: 133
Study 39325031 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintained PEEP during awakening
Number of subjects: 60
Study 39325031 — intervention group
Group type: COMPARATOR
Intervention: Zero PEEP during awakening
Number of subjects: 60
Study 39325087 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused CBT
Number of subjects: 183
Study 39325087 — intervention group
Group type: COMPARATOR
Intervention: Stepped care CBT
Number of subjects: 183
Study 39325123 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 0
Study 39325123 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for cervical cancer
Number of subjects: 0
Study 39325123 — intervention group
Group type: EXPERIMENTAL
Intervention: Catch-up vaccination
Number of subjects: 0
Study 39325123 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal self-sampling screening for HPV detection
Number of subjects: 0
Study 39325123 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic vaccination
Number of subjects: 0
Study 39325260 — intervention group
Group type: EXPERIMENTAL
Intervention: ddPCR assays for HPV16, 18, 33, 35, 56, and 59
Number of subjects: 119
Study 39325260 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment assessment of ctHPV-DNA levels
Number of subjects: 119
Study 39325260 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of ctHPV-DNA levels
Number of subjects: 119
Study 39325260 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable ctHPV-DNA posttreatment
Number of subjects: 119
Study 39325310 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP-led care
Number of subjects: 156
Study 39325310 — intervention group
Group type: COMPARATOR
Intervention: Physician-led care
Number of subjects: 156
Study 39325310 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 156
Study 39325327 — intervention group
Group type: EXPERIMENTAL
Intervention: eTEP technique
Number of subjects: 60
Study 39325327 — intervention group
Group type: COMPARATOR
Intervention: TEP technique
Number of subjects: 60
Study 39325391 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 0
Study 39325391 — intervention group
Group type: COMPARATOR
Intervention: Safety control
Number of subjects: 0
Study 39325409 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief online self-guided intervention for loneliness
Number of subjects: 0
Study 39325409 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer loneliness intervention
Number of subjects: 0
Study 39325409 — intervention group
Group type: COMPARATOR
Intervention: Active control self-guided intervention (SSI)
Number of subjects: 0
Study 39325429 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping profile
Number of subjects: 0
Study 39325429 — intervention group
Group type: COMPARATOR
Intervention: Struggling profile
Number of subjects: 0
Study 39325429 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping but concerned profile
Number of subjects: 0
Study 39325429 — intervention group
Group type: EXPERIMENTAL
Intervention: General population of NSCLC patients
Number of subjects: 0
Study 39325452 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) - weekly group or individual counseling
Number of subjects: 99
Study 39325452 — intervention group
Group type: COMPARATOR
Intervention: Clinician-delivered CBT
Number of subjects: 99
Study 39325452 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital CBT (CBT4CBT) plus brief weekly clinical monitoring
Number of subjects: 99
Study 39325453 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo (4 oral capsules, 3 times a day for 90 days)
Number of subjects: 2007
Study 39325453 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo, 4 oral capsules, 3 times a day for 90 days)
Number of subjects: 2007
Study 39325463 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral everolimus 1.5-mg daily for 42 days after surgery
Number of subjects: 7
Study 39325510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory cognitive tests administered via smartphone app 4 times per day during a 14-day data collection period.
Number of subjects: 274
Study 39325510 — intervention group
Group type: COMPARATOR
Intervention: In-person cognitive tests
Number of subjects: 274
Study 39325510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory measures of physical activity, sleep, fatigue, pain, mood, and stress
Number of subjects: 274
Study 39325510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory measures of cognitive functioning
Number of subjects: 274
Study 39325643 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 25-100 mg/day orally
Number of subjects: 341
Study 39325643 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 341
Study 39325643 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 341
Study 39325778 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation intervention (culturally adapted Western expressive writing paradigm with emotional disclosure)
Number of subjects: 240
Study 39325778 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-cultivation intervention (originates from Asian cultural values without disclosing emotions)
Number of subjects: 240
Study 39325778 — intervention group
Group type: COMPARATOR
Intervention: Control condition (writing about neutral topics)
Number of subjects: 240
Study 39325778 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation intervention
Number of subjects: 240
Study 39325778 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-cultivation intervention
Number of subjects: 240
Study 39325778 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 240
Study 39325787 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Number of subjects: 150
Study 39325787 — intervention group
Group type: COMPARATOR
Intervention: Continued medical treatment of CRS
Number of subjects: 150
Study 39325795 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person auricular point acupressure (mAPA)
Number of subjects: 0
Study 39325795 — intervention group
Group type: COMPARATOR
Intervention: Sham control (virtual APA; vAPA)
Number of subjects: 0
Study 39325795 — intervention group
Group type: COMPARATOR
Intervention: Wait-list usual care control (UC)
Number of subjects: 0
Study 39325803 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic algorithm developed using behavioral, neurophysiological, and MRI biomarkers from patients with FMD and healthy controls.
Number of subjects: 0
Study 39325803 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic value exploration of the diagnostic algorithm post-rehabilitation in a subgroup of patients with FMD.
Number of subjects: 0
Study 39325828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfizer BNT162b2 vaccine
Number of subjects: 585
Study 39326009 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg QD
Number of subjects: 787
Study 39326009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787
Study 39326037 — intervention group
Group type: EXPERIMENTAL
Intervention: GPT-4 analysis of CT scans
Number of subjects: 208
Study 39326042 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic-based interval cycling intervention
Number of subjects: 0
Study 39326042 — intervention group
Group type: COMPARATOR
Intervention: 12-week balance and stretching intervention
Number of subjects: 0
Study 39326051 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylergonovine
Number of subjects: 100
Study 39326051 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboprost
Number of subjects: 100
Study 39326323 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary or interval cytoreductive surgery (CRS)
Number of subjects: 8
Study 39326323 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 8
Study 39326356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume ≥7 mL/kg PBW
Number of subjects: 600
Study 39326356 — intervention group
Group type: COMPARATOR
Intervention: Tidal volume <7 mL/kg PBW
Number of subjects: 600
Study 39326505 — intervention group
Group type: EXPERIMENTAL
Intervention: WBI+RNI
Number of subjects: 840
Study 39326505 — intervention group
Group type: COMPARATOR
Intervention: WBI only
Number of subjects: 840
Study 39326506 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 135
Study 39326583 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg
Number of subjects: 143
Study 39326583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 39326583 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 143
Study 39326583 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 143
Study 39326675 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-corrected T1 mapping (cT1)
Number of subjects: 150
Study 39326675 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver fat content (LFC)
Number of subjects: 150
Study 39326675 — intervention group
Group type: EXPERIMENTAL
Intervention: cT1 reduction of ≥80 ms
Number of subjects: 150
Study 39326675 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver fat reduction of ≥30%
Number of subjects: 150
Study 39326699 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation (FA)
Number of subjects: 831
Study 39326699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalamin supplementation
Number of subjects: 831
Study 39326699 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR 677TT genotype with FA supplementation
Number of subjects: 831
Study 39326699 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 831
Study 39326699 — intervention group
Group type: COMPARATOR
Intervention: Suboptimal RBCF
Number of subjects: 831
Study 39326699 — intervention group
Group type: COMPARATOR
Intervention: Suboptimal plasma cobalamin status
Number of subjects: 831
Study 39326699 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking and BMI
Number of subjects: 831
Study 39326699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalamin status at labor
Number of subjects: 831
Study 39326908 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 140
Study 39326908 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy (12 weeks)
Number of subjects: 140
Study 39326908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (APM and exercise therapy)
Number of subjects: 140
Study 39326918 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag (200-1600 µg twice daily titration until individual maximum tolerated dose) + standard of care
Number of subjects: 128
Study 39326918 — intervention group
Group type: COMPARATOR
Intervention: Placebo + standard of care
Number of subjects: 128
Study 39326921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0
Study 39326921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39327049 — intervention group
Group type: COMPARATOR
Intervention: webinar (50 min virtual session standard of care)
Number of subjects: 42
Study 39327049 — intervention group
Group type: EXPERIMENTAL
Intervention: in-person education
Number of subjects: 42
Study 39327049 — intervention group
Group type: EXPERIMENTAL
Intervention: video education
Number of subjects: 42
Study 39327056 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher post-filter ionised calcium target (0.35-0.45 mmol/L)
Number of subjects: 412
Study 39327056 — intervention group
Group type: COMPARATOR
Intervention: Lower post-filter ionised calcium target (0.25-0.35 mmol/L)
Number of subjects: 412
Study 39327172 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation with movement (MWM) plus exercise
Number of subjects: 70
Study 39327172 — intervention group
Group type: COMPARATOR
Intervention: Sham mobilisation with movement plus exercise
Number of subjects: 70
Study 39327269 — intervention group
Group type: EXPERIMENTAL
Intervention: IRBD-SSS-PT (patient version)
Number of subjects: 188
Study 39327269 — intervention group
Group type: EXPERIMENTAL
Intervention: IRBD-SSS-BP (bedpartner version)
Number of subjects: 188
Study 39327291 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting time exceeding 6 months
Number of subjects: 232
Study 39327294 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypectomy repeated twice during the withdrawal phase after initial insertion of the colonoscope (study group).
Number of subjects: 406
Study 39327294 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy method with observation and polypectomy once (control group).
Number of subjects: 406
Study 39327433 — intervention group
Group type: EXPERIMENTAL
Intervention: Surufatinib (200 mg, qd, po) plus toripalimab (240 mg, d1, ivdrip) combined with etoposide (100 mg/m², d1-d3, iv, drip) and cisplatin (25 mg/m², d1-d3, ivdrip)
Number of subjects: 38
Study 39327433 — intervention group
Group type: EXPERIMENTAL
Intervention: Surufatinib, toripalimab, etoposide plus cisplatin
Number of subjects: 38
Study 39327563 — intervention group
Group type: EXPERIMENTAL
Intervention: One session of low-level laser therapy (LLLT) per week for 4 weeks
Number of subjects: 90
Study 39327563 — intervention group
Group type: EXPERIMENTAL
Intervention: Two sessions of low-level laser therapy (LLLT) per week for 4 weeks
Number of subjects: 90
Study 39327563 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sessions of low-level laser therapy (LLLT) per week for 4 weeks
Number of subjects: 90
Study 39327613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 900
Study 39327613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine (SP + AQ)
Number of subjects: 900
Study 39327613 — intervention group
Group type: COMPARATOR
Intervention: Artesunate (AS)
Number of subjects: 900
Study 39327830 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured contraceptive counseling
Number of subjects: 770
Study 39327830 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 770
Study 39327857 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF) 25 mg/day
Number of subjects: 1298
Study 39327857 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg/day
Number of subjects: 1298
Study 39327857 — intervention group
Group type: COMPARATOR
Intervention: Switch from TDF to TAF at year 2 (TDF2y → TAF6y)
Number of subjects: 1298
Study 39327857 — intervention group
Group type: COMPARATOR
Intervention: Switch from TDF to TAF at year 3 (TDF3y → TAF5y)
Number of subjects: 1298
Study 39327857 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term TAF treatment
Number of subjects: 1298
Study 39328083 — intervention group
Group type: EXPERIMENTAL
Intervention: SR group (telerehabilitation using the SR device for 20 hours over 4 weeks)
Number of subjects: 40
Study 39328083 — intervention group
Group type: COMPARATOR
Intervention: Sham device group (training with pictorial handouts and a sham device for 20 hours over 4 weeks)
Number of subjects: 40
Study 39328096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 or 30 mg (± 4-week 200-mg loading dose) for 24 weeks
Number of subjects: 718
Study 39328096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 or 30 mg for 24 weeks
Number of subjects: 718
Study 39328096 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 718
Study 39328202 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-ERAS (prehabilitation exercises with standard ERAS)
Number of subjects: 95
Study 39328202 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-ERAS
Number of subjects: 95
Study 39328202 — intervention group
Group type: COMPARATOR
Intervention: S-ERAS
Number of subjects: 95
Study 39328312 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow derived mesenchymal stromal cells (MSC)
Number of subjects: 7
Study 39328391 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 0
Study 39328391 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment expectation measurements
Number of subjects: 0
Study 39328391 — intervention group
Group type: EXPERIMENTAL
Intervention: Clusters for individualized interventions
Number of subjects: 0
Study 39328464 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-supplemented very-low-calorie diet (PSVLCD)
Number of subjects: 106
Study 39328464 — intervention group
Group type: COMPARATOR
Intervention: Control group (food-based calorie-restricted diet)
Number of subjects: 106
Study 39328464 — intervention group
Group type: EXPERIMENTAL
Intervention: PSVLCD
Number of subjects: 106
Study 39328464 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 39328508 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-h fast followed by a 48-h refeeding period
Number of subjects: 0
Study 39328832 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-guided active breaks through the 'Active Classes' web platform, lasting 5-10 minutes, moderate to vigorous intensity, twice a day, for 12 weeks.
Number of subjects: 823
Study 39328832 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 823
Study 39328832 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-guided active breaks with curricular content.
Number of subjects: 823
Study 39328897 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based lifestyle intervention via a secure web application for one year
Number of subjects: 0
Study 39328897 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 39328897 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based lifestyle intervention
Number of subjects: 0
Study 39328900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intracanalicular insert (DEX)
Number of subjects: 96
Study 39328900 — intervention group
Group type: COMPARATOR
Intervention: Placebo insert (PBO)
Number of subjects: 96
Study 39328960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis cream
Number of subjects: 60
Study 39328960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 39328985 — intervention group
Group type: EXPERIMENTAL
Intervention: SPMS
Number of subjects: 149
Study 39329073 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional vascular access (predicted by AVAS)
Number of subjects: 1034
Study 39329073 — intervention group
Group type: COMPARATOR
Intervention: Unconventional vascular access (not predicted by AVAS)
Number of subjects: 1034
Study 39329073 — intervention group
Group type: EXPERIMENTAL
Intervention: AVAS classification
Number of subjects: 1034
Study 39329073 — intervention group
Group type: COMPARATOR
Intervention: Clinician prediction of VA
Number of subjects: 1034
Study 39329073 — intervention group
Group type: EXPERIMENTAL
Intervention: AVAS classes
Number of subjects: 1034
Study 39329073 — intervention group
Group type: EXPERIMENTAL
Intervention: AVAS assessment
Number of subjects: 1034
Study 39329200 — intervention group
Group type: EXPERIMENTAL
Intervention: Muvalaplin
Number of subjects: 0
Study 39329205 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-Minded Affective Coping (BMAC)
Number of subjects: 16
Study 39329240 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol)
Number of subjects: 1372
Study 39329272 — intervention group
Group type: EXPERIMENTAL
Intervention: DNG/EE treatment
Number of subjects: 80
Study 39329336 — intervention group
Group type: EXPERIMENTAL
Intervention: Total follicle count
Number of subjects: 302
Study 39329336 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger follicles (≥5mm)
Number of subjects: 302
Study 39329336 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating E1 and E2 levels
Number of subjects: 302
Study 39330494 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of glycemic control through medical intervention (insulin introduction, changes in multi-injection therapy, pump therapy introduction, therapeutic education)
Number of subjects: 98
Study 39330494 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of glycemic control
Number of subjects: 98